switch from semaglutide to tirzepatide Switching Switch from Semaglutide to Tirzepatide:

These include: Nausea particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite These effects were generally mild to moderate in severity and tended to diminish over time as the body adjusted to the medication

Results demonstrated substantial reductions in liver fat content at 24 weeks across all active doses, with the 8 mg and 12 mg doses producing mean relative liver fat reductions of 81.4% and 82.4% respectively, compared to a +0.3% change with placebo

Appetite suppression from the GLP-1 and GIP components appears well-maintained with microdosing, particularly at twice-weekly frequency

I find the risk-benefit calculation here overwhelmingly favorable for most people

Because your cells constantly renew, these results depend on maintenance

Does CagriSema need special storage